News of Note—Vetter and Nanoform expand and WuXi Biologics plant gets FDA nod

Financial market data. Image: Pixabay
(Pixabay)

> CDMO Vetter says the expansion of its facility in suburban Chicago is nearly complete. Release

> Vaccine producer Seqirus says for the 2019-2020 flu season, it will manufacture vaccines for all four flu strains recommended by WHO using its cell-based processes. Release 

> China has taken steps to overcome drug shortages in the country including fining some companies for market concentration. Story

> WuXi Biologics announced that its Drug Substance and Drug Product manufacturing facilities at Wuxi city successfully completed a seven-day FDA surveillance inspection by three inspectors for the production of Trogarzo, the first routine GMP inspection since the product's approval. Release

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

> Helsinki, Finland-based Nanoform says it expects to begin producing drug product this year in a 600 square meter manufacturing plant it is building at Cultivator II in Viikki Life Science Park, Finland. Release

> Adare Pharmaceuticals, has an agreement with Egalet Corporation for technology that enables single-dose formulation of taste-masked, easy-to-swallow oral medications for the pediatric and geriatric populations. Release

> Coquí Radio Pharmaceuticals Corp. has received 206 acres in Oak Ridge, Tennessee, from the Department of Energy on which to build a dedicated medical isotope production facility to address the U.S. reliance on imported medical isotopes that are used for diagnosing and treating a variety of diseases. Release

Read more on

Suggested Articles

Glenmark hopes to raise cash from selling drugs outside of its focus therapeutic areas and from finding new investors for its API and innovation spinoffs.

Sun's Shanghvi took a 99% pay cut last year. Dr. Reddy's copies of Copaxone and NuvaRing were rejected by the FDA. Natco eyes China amid hardship.

Pfizer says two lots of migraine med Relpax failed to meet microbial standards and may be contaminated with genera pseudomonas and burkholderia.